Real-time Estimate
Cboe BZX
10:36:55 2024-06-03 am EDT
5-day change
1st Jan Change
22.16
USD
+2.14%
+8.63%
-7.90%
Presentation Operator MessageOperator (Operator)Good day, ladies and gentlemen, and welcome to...
Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing
May. 31
MT
Exelixis Settles Cabometyx Patent Litigation with Cipla
May. 20
MT
Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM
May. 14
Transcript : Exelixis, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
May. 14
Transcript : Exelixis, Inc. Presents at The Citizens JMP Life Sciences Conference, May-14-2024 09:30 AM
May. 14
Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target
May. 14
MT
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment
May. 10
DJ
RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept
May. 01
MT
Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours
Apr. 30
MT
Transcript : Exelixis, Inc., Q1 2024 Earnings Call, Apr 30, 2024
Apr. 30
Exelixis Guides For 2024 Revenue of $1.825-$1.925 Billion, vs CIQ Analyst Consensus of $1.91 Billion
Apr. 30
MT
Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M
Apr. 30
MT
Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29
Apr. 30
MT
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.
Apr. 30
CI
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024
Apr. 30
CI
Exelixis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 30
CI
North American Morning Briefing : Big Banks Kick -2-
Apr. 12
DJ
Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25
Apr. 11
MT
Jacqueline Wright Notifies Exelixis, Inc. of Her Decision Not to Stand for Re-Election to the Board of Directors
Mar. 29
CI
Transcript : Exelixis, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM
Mar. 13
Transcript : Exelixis, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 09:20 AM
Mar. 12
Transcript : Exelixis, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
Mar. 05
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing
Feb. 22
MT
Transcript : Exelixis, Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-13-2024 12:40 PM
Feb. 13
Transcript : Exelixis, Inc. Presents at Guggenheim Healthcare Talks| 6th Annual Biotechnology Conference, Feb-08-2024 09:00 AM
Feb. 08
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
More about the company
Last Close Price
21.69
USD
Average target price
26.59
USD
Spread / Average Target
+22.59%
Consensus
1st Jan change
Capi.
-7.90% 6.32B +14.33% 118B +13.72% 106B -2.51% 24.28B +0.76% 21.96B -8.96% 18.16B -42.12% 16.37B -17.50% 15.56B +6.00% 13.63B +29.48% 12.27B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1